---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-22-013758"
form_type: "8-K"
ticker: "ABSI"
cik: "0001672688"
company_name: "Absci Corp"
filed_at: "2022-05-11T23:59:59+00:00"
generated_at: "2026-06-25T21:04:49.400275+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Absci Q1 net loss $29.5M; cash $226M; signs Merck collaboration worth up to $610M

## Summary
- Net loss of $29.5M in Q1 2022 vs $11.0M in Q1 2021; R&D expense $15.8M, SG&A $10.9M.
- Cash and equivalents $226.0M as of March 31, 2022, sufficient to fund operations through end of 2024.
- Entered Merck collaboration for Bionic Enzyme generation; potential $610M in upfront and milestones plus royalties.
- Unveiled AI models for antibody affinity prediction and naturalness scoring; partnered with NVIDIA.
- Reiterates guidance of at least 8 new Active Programs in 2022 (60% YoY growth); 3 signed year-to-date.

## SEC filing metadata
- accession: 0001628280-22-013758
- form_type: 8-K
- ticker: ABSI
- cik: 0001672688
- company_name: Absci Corp
- filed_at: 2022-05-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1672688/000162828022013758/0001628280-22-013758-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1672688/000162828022013758/absc-20220511.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-22-013758
- JSON: https://secwatch.observer/filing/0001628280-22-013758.json
- Plain text: https://secwatch.observer/filing/0001628280-22-013758.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.